ImmunoPulse: Interim Phase II data

Interim data from a single-arm, open-label, U.S. Phase II trial in 21 evaluable patients with stage III or IV cutaneous and in-transit metastatic melanoma showing that ImmunoPulse delivered directly into tumors with the company's OMS ElectroImmunotherapy technology led to an ORR, defined as a >=30% reduction in summed size of lesions, in 8 patients at day 180. Specifically, ImmunoPulse led to 6 partial responses and 2 complete responses lasting >=6 months, plus 2 cases of clinically beneficial stable disease for >=3 months. Patients received ImmunoPulse applied to up to 4 lesions on days 1, 5 and 8 at a maximum dose of 1.5 mg per cycle. Data were presented at the Advances in Cancer Immunotherapy meeting in San Francisco. ...